NLS Pharmaceutics (NLSP) CEO Issues Letter to Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq rise as chips recover, Broadcom gains on Apple deal
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- S&P 500, Nasdaq rise as chips recover, Broadcom gains on Apple deal
NLS Pharmaceutics CEO Issues Letter to Shareholders
August 28, 2023 7:31 AM EDTZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:
NLS Pharmaceutics CEO Issues Letter to Shareholders
To our Shareholders and Friends,
Though we may have been quiet recently, I wanted to assure you that the team here at NLS has been... More
